Dallas, TX -- (SBWIRE) -- 06/25/2015 -- The report "Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects.

Complete report on Deep Vein Thrombosis (DVT) with 24 market data tables and 15 figures, spread across 80 pages is available at http://www.rnrmarketresearch.com/deep-vein-thrombosis-dvt-pipeline-review-h1-2015-market-report.html .

Companies discussed in this Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2015 report include Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Generex Biotechnology Corporation, Laboratorios Farmaceuticos Rovi, S.A., Merrion Pharmaceuticals Plc, Tobira Therapeutics, Inc.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are apixaban, enoxaparin biosimilar, enoxaparin sodium, fondaparinux sodium, REG-2, rivaroxaban, RNAi Oligonucleotide for DVT, Small Molecules for Hematological Disorders and Cancer, TRX-1.

Order a purchase copy of this report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=393494
(This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report includes:

-May 04, 2015: Bayer's Xarelto Approved in China for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and for the Treatment of Deep Vein Thrombosis

-Apr 07, 2015: Xarelto Litigation Update: Legal-Bay Lawsuit Settlement Funding Reports Issuance of New Court Documents

-Mar 30, 2015: New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits

-Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO

-Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE

-Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy

-Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE

-Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE

-Mar 14, 2014: U.S. FDA Approves Eliquis (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery

-Dec 19, 2013: FDA Accepts For Review ELIQUIS Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis And Pulmonary Embolism, And For The Reduction In The Risk Of Recurrent DVT And PE

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

List of Tables
Number of Products under Development for Deep Vein Thrombosis (DVT), H1 2015 8
Number of Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Deep Vein Thrombosis (DVT) - Pipeline by Bayer AG, H1 2015 17
Deep Vein Thrombosis (DVT) - Pipeline by Bristol-Myers Squibb Company, H1 2015 18
Deep Vein Thrombosis (DVT) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 19
Deep Vein Thrombosis (DVT) - Pipeline by Generex Biotechnology Corporation, H1 2015 20
Deep Vein Thrombosis (DVT) - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H1 2015 21
Deep Vein Thrombosis (DVT) - Pipeline by Merrion Pharmaceuticals Plc, H1 2015 22
Deep Vein Thrombosis (DVT) - Pipeline by Tobira Therapeutics, Inc., H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Deep Vein Thrombosis (DVT) Therapeutics - Recent Pipeline Updates, H1 2015 48
Deep Vein Thrombosis (DVT) - Dormant Projects, H1 2015 66
Deep Vein Thrombosis (DVT) - Discontinued Products, H1 2015 67

List of Figures
Number of Products under Development for Deep Vein Thrombosis (DVT), H1 2015 8
Number of Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 14
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Top 10 Targets, H1 2015 25
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Top 10 Routes of Administration, H1 2015 29
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30
Number of Products by Top 10 Molecule Types, H1 2015 31
Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Explore more reports on Hematology Therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/hematology-therapeutics

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.